Recursion Pharmaceuticals (NASDAQ:RXRX) Given New $8.00 Price Target at Needham & Company LLC

Recursion Pharmaceuticals (NASDAQ:RXRX - Free Report) had its price target reduced by Needham & Company LLC from $11.00 to $8.00 in a research report sent to investors on Tuesday,Benzinga reports. Needham & Company LLC currently has a buy rating on the stock.

A number of other brokerages have also commented on RXRX. Leerink Partners dropped their price target on Recursion Pharmaceuticals from $7.00 to $6.00 and set a "market perform" rating for the company in a research note on Friday, February 28th. Morgan Stanley lowered their target price on shares of Recursion Pharmaceuticals from $10.00 to $8.00 and set an "equal weight" rating for the company in a report on Thursday, April 10th. KeyCorp cut their target price on Recursion Pharmaceuticals from $12.00 to $10.00 and set an "overweight" rating on the stock in a research note on Wednesday, January 8th. Finally, Cowen restated a "hold" rating on shares of Recursion Pharmaceuticals in a research note on Friday, February 28th. Four research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to MarketBeat.com, Recursion Pharmaceuticals presently has an average rating of "Hold" and an average target price of $7.60.

Recursion Pharmaceuticals Trading Up 0.8 %

Shares of NASDAQ:RXRX traded up $0.04 on Tuesday, reaching $4.20. 22,428,449 shares of the company traded hands, compared to its average volume of 12,764,775. The company has a current ratio of 4.35, a quick ratio of 4.35 and a debt-to-equity ratio of 0.04. The business's 50-day simple moving average is $5.62 and its 200 day simple moving average is $6.69. The stock has a market capitalization of $1.69 billion, a P/E ratio of -2.74 and a beta of 0.99. Recursion Pharmaceuticals has a 52 week low of $3.79 and a 52 week high of $12.36.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last issued its earnings results on Monday, May 5th. The company reported ($0.50) EPS for the quarter, missing the consensus estimate of ($0.44) by ($0.06). The firm had revenue of $14.75 million during the quarter, compared to analysts' expectations of $18.12 million. Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The firm's quarterly revenue was up 7.2% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.39) earnings per share. As a group, equities analysts anticipate that Recursion Pharmaceuticals will post -1.57 EPS for the current fiscal year.

Institutional Trading of Recursion Pharmaceuticals

Hedge funds have recently bought and sold shares of the company. Decker Retirement Planning Inc. purchased a new stake in shares of Recursion Pharmaceuticals in the 4th quarter worth $26,000. Private Trust Co. NA bought a new stake in Recursion Pharmaceuticals during the 4th quarter worth approximately $27,000. GAMMA Investing LLC boosted its position in shares of Recursion Pharmaceuticals by 1,979.2% in the fourth quarter. GAMMA Investing LLC now owns 5,198 shares of the company's stock worth $35,000 after purchasing an additional 4,948 shares during the period. Farther Finance Advisors LLC increased its stake in shares of Recursion Pharmaceuticals by 21.1% in the fourth quarter. Farther Finance Advisors LLC now owns 7,757 shares of the company's stock worth $52,000 after purchasing an additional 1,353 shares in the last quarter. Finally, NewEdge Advisors LLC lifted its stake in shares of Recursion Pharmaceuticals by 43.7% during the 4th quarter. NewEdge Advisors LLC now owns 7,847 shares of the company's stock valued at $53,000 after buying an additional 2,387 shares in the last quarter. Hedge funds and other institutional investors own 89.06% of the company's stock.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.